GLP-1 Drugs Linked to Temporary Hair Loss

The analysis drew on electronic health records from the University of Pennsylvania Health System, covering January 2019 through September 2024, according to reporting from Medical News Today. Researchers compared two large groups of people being treated for type 2 diabetes: about 12,004 GLP-1 users against 15,221 people taking SGLT-2 inhibitors, and 11,964 GLP-1 users against 11,238 people taking DPP-4 inhibitors.

The signal showed up in both comparisons. Set against the SGLT-2 group, GLP-1 users had a 37% higher chance of experiencing hair loss. Set against the DPP-4 group, that figure climbed to 68%. What matters just as much as the numbers is the type: the hair loss in question was non-scarring alopecia, a category that includes telogen effluvium and androgenetic alopecia and, unlike scarring forms, does not permanently damage the hair follicle.

One caveat sits at the heart of all this. Because the study was observational, it can reveal a pattern but cannot prove that the medication itself directly caused the shedding. It also compared GLP-1s only against other diabetes treatments, so it does not tell us what the risk looks like for someone taking these drugs for weight loss alone.

The leading explanation has less to do with the drug reaching for your hair and more to do with how quickly the body is changing. Rapid weight loss is a well-recognized trigger for telogen effluvium, a temporary, diffuse shedding that has already been connected with weight loss in the medical literature. When the body moves through a sudden shift, a larger share of hair follicles can slip into their resting phase at once and shed a few months later.

Mir Ali, MD, a bariatric surgeon and medical director of MemorialCare Surgical Weight Loss Center in Fountain Valley, California, who was not involved in the study, sees this pattern often. "The findings regarding the increased risk of alopecia compared to SGLT-2 inhibitors (37%) and DPP-4 inhibitors (68%) are notable, though not entirely surprising given that significant weight loss by any means can result in hair loss," he said. He added that "the medication acts as a catalyst for weight loss, but the resulting physiological stress and hormonal changes are often the direct trigger for telogen effluvium."

Nutrition plays a supporting role, too. Eating less can leave some people short on the building blocks hair needs, and the study authors point to gaps in biotin, iron, and zinc as possible contributors. GLP-1 users can be surprisingly prone to these shortfalls, from quietly dwindling magnesium levels to the iron and zinc gaps flagged here. Changes in thyroid function and the slower stomach emptying these drugs cause, which can alter how oral medications are absorbed, may add to the picture as well.

A 68% jump grabs attention, but it is only half the picture. In real terms, roughly 6 to 7 of every 1,000 people taking GLP-1 medications experienced hair loss each year, which means the overwhelming majority did not. A large relative increase applied to an already small number stays a small number, a nuance worth holding onto as more people than ever begin these medications.

Hair loss is not an entirely new footnote for this drug class, either. The FDA's prescribing information for Wegovy lists hair loss among reported effects, including in newer higher-dose trial data, with higher rates among female participants. Seeing the same signal surface across a real-world study and formal drug labeling is part of what makes researchers comfortable naming it, while still keeping its low frequency in view.

Some people simply start with less margin. Manish Mittal, MD, a hair transplant surgeon who was not involved in the study, put it plainly: "The vast majority of patients will never experience clinically significant hair loss, but the study reinforces that shedding can occur in a small proportion of people and is something clinicians should discuss before treatment."

The people most likely to notice, he said, are "people who lose weight very rapidly, have pre-existing nutritional deficiencies, women with low iron stores, individuals recovering from bariatric surgery, or those with underlying androgenetic hair loss," because they "already have reduced hair reserve." Low iron deserves its own mention here, since iron supports the normal growth and repair of the body's tissues, and shortfalls are especially common among women who menstruate.

For anyone in these groups, thinking about the plate early can help. Building meals around foods that naturally support GLP-1 activity and steady nutrition is part of the conversation experts say is worth having up front.

The clinicians who spoke about the findings converged on a reassuring first point: shedding alone is rarely a reason to abandon a treatment that is working.

Opel Baker, a general practitioner at the Mayfield Clinic who was not involved in the study, framed the day-to-day approach this way: "The most important advice is not to panic and not to discontinue treatment without medical advice. We encourage patients to lose weight at a sustainable pace rather than as quickly as possible, prioritize adequate protein intake, and attend regular follow-up appointments." If shedding does appear, he noted, "it's sensible to assess dietary intake and, where clinically indicated, arrange blood tests to check for iron deficiency, thyroid disease, vitamin B12, or other contributing factors."

Protein and micronutrients come up again and again. Ali recommends that patients "maintain adequate protein intake and supplement appropriately with key micronutrients, especially iron, zinc, and biotin, while on these medications," with basic nutritional labs checked if hair loss becomes a concern. Covering those basics can feel harder when appetite drops, which is why many GLP-1 users lean on protein- and satiety-focused foods to fill the gaps.

Timing helps set expectations. Shedding from telogen effluvium often surfaces around three months after a trigger, according to the British Association of Dermatologists, so a change noticed months into treatment may trace back to the earlier, fastest stretch of weight loss. Mittal suggests that if shedding is still increasing after three to six months, seeking assessment early — rather than assuming it is permanent — can help tell temporary telogen effluvium apart from an unrelated hair condition.

For most people, the conversation does not end at hair. These medications are increasingly valued for benefits that reach well beyond the scale. In 2026, the American Heart Association recommended GLP-1-based therapies, for the first time, for certain people with obesity or type 2 diabetes and added cardiovascular risk factors, as a way to lower the odds of heart events. It is a reminder of how much can sit on the other side of the ledger.

Ali summed up the trade-off many patients face: "For the vast majority of patients seeking treatment for obesity or diabetes, the metabolic benefits of GLP-1s significantly outweigh the risk of temporary, non-scarring hair loss, which usually resolves once weight stabilizes." As GLP-1s continue to expand into new uses, that kind of clear-eyed weighing — a small, usually reversible risk set against a meaningful benefit — is exactly the discussion the new study invites patients and their clinicians to have.